Liver fibrosis-induced muscle atrophy is mediated by elevated levels of circulating TNFα.
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
07 01 2021
07 01 2021
Historique:
received:
12
06
2020
accepted:
15
12
2020
revised:
14
12
2020
entrez:
8
1
2021
pubmed:
9
1
2021
medline:
1
10
2021
Statut:
epublish
Résumé
Liver cirrhosis is a critical health problem associated with several complications, including skeletal muscle atrophy, which adversely affects the clinical outcome of patients independent of their liver functions. However, the precise mechanism underlying liver cirrhosis-induced muscle atrophy has not been elucidated. Here we show that serum factor induced by liver fibrosis leads to skeletal muscle atrophy. Using bile duct ligation (BDL) model of liver injury, we induced liver fibrosis in mice and observed subsequent muscle atrophy and weakness. We developed culture system of human primary myotubes that enables an evaluation of the effects of soluble factors on muscle atrophy and found that serum from BDL mice contains atrophy-inducing factors. This atrophy-inducing effect of BDL mouse serum was mitigated upon inhibition of TNFα signalling but not inhibition of myostatin/activin signalling. The BDL mice exhibited significantly up-regulated serum levels of TNFα when compared with the control mice. Furthermore, the mRNA expression levels of Tnf were markedly up-regulated in the fibrotic liver but not in the skeletal muscles of BDL mice. The gene expression analysis of isolated nuclei revealed that Tnf is exclusively expressed in the non-fibrogenic diploid cell population of the fibrotic liver. These findings reveal the mechanism through which circulating TNFα produced in the damaged liver mediates skeletal muscle atrophy. Additionally, this study demonstrated the importance of inter-organ communication that underlies the pathogenesis of liver cirrhosis.
Identifiants
pubmed: 33414474
doi: 10.1038/s41419-020-03353-5
pii: 10.1038/s41419-020-03353-5
pmc: PMC7791043
doi:
Substances chimiques
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11Références
Hepatol Res. 2016 Sep;46(10):951-63
pubmed: 27481650
Liver Int. 2018 May;38(5):851-857
pubmed: 29323441
Hepatology. 2005 May;41(5):1046-55
pubmed: 15841463
Nature. 1997 May 1;387(6628):83-90
pubmed: 9139826
Hepatology. 2006 Aug;44(2):389-98
pubmed: 16871588
Nat Commun. 2013;4:2823
pubmed: 24264436
Australas J Ageing. 2011 Jun;30(2):89-92
pubmed: 21672118
Middle East J Dig Dis. 2018 Jul;10(3):133-148
pubmed: 30186577
Basic Res Cardiol. 2017 Jul;112(4):48
pubmed: 28647906
Methods Mol Biol. 2016;1460:241-53
pubmed: 27492177
Mol Cell Biol. 2003 Jun;23(11):4013-25
pubmed: 12748302
Cell. 2004 Oct 15;119(2):285-98
pubmed: 15479644
PLoS One. 2007 Aug 29;2(8):e789
pubmed: 17726519
Curr Top Dev Biol. 2011;96:85-119
pubmed: 21621068
Exp Anim. 2011;60(5):481-7
pubmed: 22041285
Gastroenterology. 2012 Sep;143(3):765-776.e3
pubmed: 22687286
J Hepatol. 1994 Jan;20(1):122-8
pubmed: 8201213
J Surg Res. 1997 Oct;72(2):129-34
pubmed: 9356233
J Hepatol. 2019 Jan;70(1):151-171
pubmed: 30266282
Acta Cir Bras. 2012 Aug;27(8):589-94
pubmed: 22850713
Sci Rep. 2019 Feb 20;9(1):2420
pubmed: 30787413
Hepatol Res. 2016 Jul;46(8):743-51
pubmed: 26579878
Physiol Rev. 2008 Jan;88(1):125-72
pubmed: 18195085
ISRN Obes. 2012 Sep 30;2012:647348
pubmed: 24533207
Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:315-339
pubmed: 30148697
J Vis Exp. 2015 Feb 10;(96):
pubmed: 25741630
Curr Opin Gastroenterol. 2016 May;32(3):159-65
pubmed: 26974417
Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18162-7
pubmed: 24145431
Crit Rev Biochem Mol Biol. 2014 Jan-Feb;49(1):59-68
pubmed: 24237131
Lancet Gastroenterol Hepatol. 2020 Mar;5(3):245-266
pubmed: 31981519
J Hepatol. 2015 Apr;62(1 Suppl):S15-24
pubmed: 25920084
Nature. 2020 Jul;583(7817):590-595
pubmed: 32669714
Physiol Rep. 2017 Apr;5(7):
pubmed: 28364027
Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1341-50
pubmed: 16849630
J Hepatol. 2006 Jan;44(1):217-31
pubmed: 16298014
Age Ageing. 2010 Jul;39(4):412-23
pubmed: 20392703
PLoS One. 2017 Oct 24;12(10):e0186990
pubmed: 29065187
Anesth Analg. 2010 Sep;111(3):707-9
pubmed: 20686014
Front Cell Dev Biol. 2018 Sep 04;6:108
pubmed: 30234113
Ann Neurol. 2008 May;63(5):561-71
pubmed: 18335515
Nutrients. 2020 Feb 20;12(2):
pubmed: 32093198
Hepatology. 2003 Nov;38(5):1188-98
pubmed: 14578857
J Hepatol. 2016 Nov;65(5):929-937
pubmed: 27318325
Nat Rev Immunol. 2014 Mar;14(3):181-94
pubmed: 24566915
J Am Geriatr Soc. 2010 Feb;58(2):312-7
pubmed: 20070416
Clin Nutr. 2010 Aug;29(4):441-7
pubmed: 20116909
J Physiol. 2009 Apr 1;587(Pt 7):1593-605
pubmed: 19204053
Cytokine. 2005 Mar 7;29(5):236-44
pubmed: 15760680
FASEB J. 2005 Mar;19(3):362-70
pubmed: 15746179
Nat Commun. 2018 Oct 22;9(1):4383
pubmed: 30348985
Sci Signal. 2019 Oct 29;12(605):
pubmed: 31662486
Fibrogenesis Tissue Repair. 2013 Oct 01;6(1):19
pubmed: 24274743
J Am Soc Nephrol. 2018 Aug;29(8):2069-2080
pubmed: 29980650
J Hepatol. 2016 Dec;65(6):1232-1244
pubmed: 27515775
Am J Clin Nutr. 2006 Sep;84(3):475-82
pubmed: 16960159
Nat Commun. 2017 Apr 28;8:15153
pubmed: 28452368
Int Immunopharmacol. 2018 Mar;56:148-155
pubmed: 29414645
Cell Rep. 2017 Nov 14;21(7):1982-1993
pubmed: 29141227
Gut. 2005 Apr;54(4):540-5
pubmed: 15753541
Nutrition. 2010 Apr;26(4):405-10
pubmed: 19632092
Cell Metab. 2015 Jul 7;22(1):164-74
pubmed: 26001423